Doheny Asset Management CA Sells 26,210 Shares of RxSight, Inc. (NASDAQ:RXST)

Doheny Asset Management CA trimmed its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 40.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,300 shares of the company's stock after selling 26,210 shares during the quarter. RxSight comprises about 1.0% of Doheny Asset Management CA's holdings, making the stock its 28th largest position. Doheny Asset Management CA owned 0.10% of RxSight worth $1,351,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in RxSight by 17.7% during the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company's stock worth $40,398,000 after purchasing an additional 122,775 shares during the last quarter. Victory Capital Management Inc. lifted its stake in RxSight by 21.0% during the third quarter. Victory Capital Management Inc. now owns 259,864 shares of the company's stock worth $12,845,000 after purchasing an additional 45,161 shares during the last quarter. Barclays PLC lifted its stake in RxSight by 389.8% during the third quarter. Barclays PLC now owns 58,786 shares of the company's stock worth $2,906,000 after purchasing an additional 46,783 shares during the last quarter. State Street Corp lifted its stake in RxSight by 8.3% during the third quarter. State Street Corp now owns 817,671 shares of the company's stock worth $40,417,000 after purchasing an additional 62,349 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in RxSight by 28.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 285,329 shares of the company's stock worth $14,104,000 after purchasing an additional 62,507 shares during the last quarter. 78.78% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Insider Transactions at RxSight

In other news, Director Tamara Fountain sold 7,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total value of $179,970.00. Following the completion of the transaction, the director now owns 24,793 shares of the company's stock, valued at approximately $637,428.03. This represents a 22.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jesse Anderson Corley bought 1,443 shares of the firm's stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average cost of $31.18 per share, with a total value of $44,992.74. Following the transaction, the director now directly owns 1,443 shares in the company, valued at approximately $44,992.74. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 9.36% of the company's stock.

RxSight Price Performance

RXST traded down $0.88 during midday trading on Wednesday, reaching $24.85. 661,227 shares of the company's stock traded hands, compared to its average volume of 527,728. The firm has a fifty day moving average of $30.19 and a two-hundred day moving average of $40.58. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -29.94 and a beta of 1.22. RxSight, Inc. has a 52 week low of $24.64 and a 52 week high of $66.54.

RxSight (NASDAQ:RXST - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.25). RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The firm had revenue of $40.21 million for the quarter, compared to analysts' expectations of $40.23 million. Sell-side analysts forecast that RxSight, Inc. will post -0.7 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. JPMorgan Chase & Co. lowered their target price on RxSight from $62.00 to $40.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus lowered their target price on RxSight from $33.00 to $28.00 and set a "hold" rating for the company in a research note on Wednesday. Wells Fargo & Company lowered their target price on RxSight from $40.00 to $35.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. UBS Group assumed coverage on RxSight in a research note on Friday, December 6th. They issued a "buy" rating and a $52.00 target price for the company. Finally, Needham & Company LLC reissued a "buy" rating and issued a $43.00 target price on shares of RxSight in a research note on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $51.00.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.